{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:15:32Z","timestamp":1793304932635,"version":"4.5.0"},"reference-count":154,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2002,1,4]],"date-time":"2002-01-04T00:00:00Z","timestamp":1010102400000},"content-version":"vor","delay-in-days":1313,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1998,6]]},"abstract":"<jats:p>Accumulating evidence indicates that CYP2C9 ranks amongst the most important drug metabolizing enzymes in humans. Substrates for CYP2C9 include fluoxetine, losartan, phenytoin, tolbutamide, torsemide, S\u2010warfarin, and numerous NSAIDs. CYP2C9 activity<jats:italic>in vivo<\/jats:italic>is inducible by rifampicin. Evidence suggests that CYP2C9 substrates may also be induced variably by carbamazepine, ethanol and phenobarbitone. Apart from the mutual competitive inhibition which may occur between alternate substrates, numerous other drugs have been shown to inhibit CYP2C9 activity<jats:italic>in vivo<\/jats:italic>and\/or<jats:italic>in vitro<\/jats:italic>. Clinically significant inhibition may occur with coadministration of amiodarone, fluconazole, phenylbutazone, sulphinpyrazone, sulphaphenazole and certain other sulphonamides. Polymorphisms in the coding region of the<jats:italic>CYP2C9<\/jats:italic>gene produce variants at amino acid residues 144 (Arg144Cys) and 359 (Ile359Leu) of the CYP2C9 protein. Individuals homozygous for Leu359 have markedly diminished metabolic capacities for most CYP2C9 substrates, although the frequency of this allele is relatively low. Consistent with the modulation of enzyme activity by genetic and other factors, wide interindividual variability occurs in the elimination and\/or dosage requirements of prototypic CYP2C9 substrates. Individualisation of dose is essential for those CYP2C9 substrates with a narrow therapeutic index.<\/jats:p>","DOI":"10.1046\/j.1365-2125.1998.00721.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T04:30:50Z","timestamp":1047357050000},"page":"525-538","source":"Crossref","is-referenced-by-count":677,"title":["Cytochrome P4502C9: an enzyme of major importance in human drug metabolism"],"prefix":"10.1111","volume":"45","author":[{"given":"John O.","family":"Miners","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald J.","family":"Birkett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,1,4]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199602000-00002"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.3109\/10408449209145319"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(92)90107-H"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(92)90140-2"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(90)90006-N"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-7743(08)60744-7"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(93)90043-J"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00418a039"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199412000-00001"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00292a019"},{"key":"e_1_2_6_12_2","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0021-9258(17)36183-5","article-title":"Human liver microsomal cytochrome P450 mephenytoin 4\u2032\u2013hydroxylase, a prototype genetic polymorphism of drug metabolism: Purification and characterization of two similar forms involved in the reaction.","volume":"261","author":"Shimada T","year":"1986","journal-title":"J Biol Chem"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/15.23.10053"},{"key":"e_1_2_6_14_2","first-page":"26","article-title":"Human cytochrome P450 PB\u20101: A multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10.","volume":"42","author":"Meehan RR","year":"1988","journal-title":"Am J Human Genet"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00227a012"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2890533"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00378a016"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jbchem.a122145"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0021-9258(18)48462-1","article-title":"Substrate recognition sites in cytochrome P\u2010450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences.","volume":"267","author":"Gotoh O","year":"1992","journal-title":"J Biol Chem"},{"key":"e_1_2_6_20_2","first-page":"236","article-title":"Characterisation of an in vitro model for assessing polymorphic metabolism by CYP2C9: Involvement in the mechanism of deficient losartan metabolism.","volume":"10","author":"Wong BK","year":"1996","journal-title":"ISSX Proceedings"},{"key":"e_1_2_6_21_2","first-page":"239","article-title":"Determinants of substrate and inhibitor specificities of human CYP2C9.","volume":"10","author":"Haining RL","year":"1996","journal-title":"ISSX Proceedings"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199302000-00001"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00033a007"},{"key":"e_1_2_6_24_2","first-page":"260","article-title":"Putative active site model for cytochrome P4502C9 (tolbutamide hydroxylase).","volume":"24","author":"Jones BC","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_25_2","first-page":"1","article-title":"Three dimensional quantitative structure\u2010activity relationship for inhibitors of cytochrome P4502C9.","volume":"24","author":"Jones JP","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.1996.0161"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199612000-00002"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(88)90522-9"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1988.tb03359.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(91)91680-B"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0076-6879(96)72017-7"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498259509061850"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1990.46"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00614553"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1977225part1573"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00322a014"},{"key":"e_1_2_6_37_2","first-page":"103","article-title":"Kinetics of carboxytolbutamide excretion following tolbutamide and carboxytolbutamide administration.","volume":"132","author":"Nelson E","year":"1961","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1991.tb05499.x"},{"key":"e_1_2_6_39_2","first-page":"1076","article-title":"Human hepatic cytochrome P4502C9 catalyzes the rate\u2010limiting pathway of torsemide metabolism.","volume":"272","author":"Miners JO","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_40_2","first-page":"442","article-title":"Tolbutamide and mephenytoin hydroxylation by human cytochromes P450 in the CYP2C subfamily.","volume":"252","author":"Relling MV","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_41_2","unstructured":"TassaneeyakulWPhD Thesis Flinders University of South Australia 1994."},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-198507030-00008"},{"key":"e_1_2_6_43_2","first-page":"106","article-title":". The effect of different sulphonamides on phenytoin metabolism in man.","volume":"624","author":"Molholm\u2010Hansen J","year":"1979","journal-title":"Acta Med Scand"},{"key":"e_1_2_6_44_2","first-page":"975","article-title":"Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.","volume":"22","author":"Hall SD","year":"1994","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_45_2","first-page":"494","article-title":"Co\u2010regulation of phenytoin and tolbutamide metabolism in humans.","volume":"34","author":"Tassaneeyakul W","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1986.3"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1021\/tx00025a009"},{"key":"e_1_2_6_48_2","first-page":"414","article-title":"Warfarin\u2010fluconazole I. Inhibition of human cytochrome P450 dependent metabolism of warfarin by fluconazole: in vitro studies.","volume":"24","author":"Kunze KL","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(97)00143-3"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(95)00048-5"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(96)85085-4"},{"key":"e_1_2_6_52_2","first-page":"126","article-title":"[O\u2010methyl14C]naproxen O\u2010demethylase activity in human liver microsomes. Evidence for the involvement of cytochrome P4501A2 and P4502C9\/10.","volume":"24","author":"Rodrigues AD","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(91)90065-T"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(93)90285-B"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00226332"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(92)90226-F"},{"key":"e_1_2_6_57_2","first-page":"139","article-title":"Biotransformation by hepatic P450TB (CYP2C) controls mefenamic acid elimination.","volume":"55","author":"Bonnabry P","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_6_58_2","first-page":"834","article-title":"Metabolism of aceclofenac in humans.","volume":"24","author":"Bort R","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_59_2","first-page":"164","article-title":"Pharmacokinetics and metabolism of torsemide in man.","volume":"38","author":"Neugebauer G","year":"1988","journal-title":"Arzneim.-Forsch"},{"key":"e_1_2_6_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1993.tb17752.x"},{"key":"e_1_2_6_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(91)90627-H"},{"key":"e_1_2_6_62_2","first-page":"326","article-title":"Tienilic\u2010induced autoimmune hepatitis: Anti\u2010liver and \u2010kidney microsomal type 2 autoantibodies recognise a three\u2010site conformational epitope on cytochrome P4502C9.","volume":"50","author":"Lecouer S","year":"1996","journal-title":"Mol Pharmacol"},{"key":"e_1_2_6_63_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.05382.x"},{"key":"e_1_2_6_64_2","first-page":"177","article-title":"Human cytochromes mediating N\u2010demethylation of fluoxetine in vitro.","volume":"61","author":"Von Moltke LL","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_6_65_2","first-page":"207","article-title":"Biotransformation of losartan to its active carboxylic metabolite in human liver microsomes. Role of cytochrome P450 2C and 3A subfamily members.","volume":"23","author":"Stearns RA","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_66_2","first-page":"110","article-title":"Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT\u2010001).","volume":"25","author":"Kumar GN","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_67_2","first-page":"241","article-title":"Human hepatic microsomal metabolism of \u03941\u2010tetrahydrocannabinol.","volume":"20","author":"Bornheim LM","year":"1992","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(93)90467-B"},{"key":"e_1_2_6_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(94)00457-W"},{"key":"e_1_2_6_70_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199208000-00003"},{"key":"e_1_2_6_71_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198325060-00004"},{"key":"e_1_2_6_72_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199018010-00003"},{"key":"e_1_2_6_73_2","first-page":"187","article-title":"Effect of high dose barbiturate therapy on phenytoin pharmacokinetics.","volume":"51","author":"Oda Y","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_6_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)80004-X"},{"key":"e_1_2_6_75_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-198609000-00012"},{"key":"e_1_2_6_76_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1977225part2735"},{"key":"e_1_2_6_77_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-196907000-00005"},{"key":"e_1_2_6_78_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.178"},{"key":"e_1_2_6_79_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1987.168"},{"key":"e_1_2_6_80_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00614021"},{"key":"e_1_2_6_81_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1985.tb05071.x"},{"key":"e_1_2_6_82_2","first-page":"202","article-title":"Effects of erythromycin or rifampin on steady state losartan kinetics in healthy volunteers.","volume":"61","author":"Williamson KM","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_6_83_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1989.104"},{"key":"e_1_2_6_84_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1987.149"},{"key":"e_1_2_6_85_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.39"},{"key":"e_1_2_6_86_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1976.tb06772.x"},{"key":"e_1_2_6_87_2","doi-asserted-by":"crossref","unstructured":"SerlinMJ MossmanS SibeonRG et al.Cimetidine: Interaction with oral anticoagulants in man.Lancet1979;ii:317\u2013319","DOI":"10.1016\/S0140-6736(79)90340-4"},{"key":"e_1_2_6_88_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00542190"},{"key":"e_1_2_6_89_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1991.tb03940.x"},{"key":"e_1_2_6_90_2","article-title":"Effect of azole antifungals on human microsomal metabolism of diclofenac and midazolam.","volume":"38","author":"Hargreaves JA","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_6_91_2","first-page":"203","article-title":"Fluconazole significantly alters the pharmacokinetics of losartan but not eprosartan.","volume":"61","author":"Kazierad DJ","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_6_92_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1991.49"},{"key":"e_1_2_6_93_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.Supplement_3.S327"},{"key":"e_1_2_6_94_2","first-page":"422","article-title":"Warfarin\u2010fluconazole II. A metabolically based drug interaction.","volume":"24","author":"Black DJ","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_95_2","first-page":"429","article-title":"Warfarin\u2010fluconazole III. A rational approach to management of a metabolically based drug interaction.","volume":"24","author":"Kunze KL","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_96_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.78"},{"key":"e_1_2_6_97_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1989.tb05410.x"},{"key":"e_1_2_6_98_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.1996.177"},{"key":"e_1_2_6_99_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1992.tb04111.x"},{"key":"e_1_2_6_100_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050094"},{"key":"e_1_2_6_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-9236(95)90054-3"},{"key":"e_1_2_6_102_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI107711"},{"key":"e_1_2_6_103_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00548400"},{"key":"e_1_2_6_104_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00548401"},{"key":"e_1_2_6_105_2","first-page":"659","article-title":"Inhibition of S\u2010warfarin metabolism by sulfinpyrazone and its metabolites.","volume":"23","author":"He M","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(63)90847-X"},{"key":"e_1_2_6_107_2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.0954-6820.1979.tb00729.x","article-title":"The effect of different sulfonamides on phenytoin metabolism in man.","volume":"24","author":"Hansen JM","year":"1979","journal-title":"Acta Med Scand"},{"key":"e_1_2_6_108_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1985.tb05102.x"},{"key":"e_1_2_6_109_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1975176731"},{"key":"e_1_2_6_110_2","first-page":"186","article-title":"Effect of zafirlukast on the pharmacokinetics of R\u2010 and S\u2010warfarin in healthy men.","volume":"61","author":"Suttle AB","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_6_111_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1984.tb02555.x"},{"key":"e_1_2_6_112_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1987.tb03115.x"},{"key":"e_1_2_6_113_2","unstructured":"AbernethyDR KaminskyLS DickinsonTHSelective inhibition of warfarin metabolism by diltiazem in humans1991;257:411\u2013416"},{"key":"e_1_2_6_114_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1987.104"},{"key":"e_1_2_6_115_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1988.tb05285.x"},{"key":"e_1_2_6_116_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1985.63"},{"key":"e_1_2_6_117_2","first-page":"182","article-title":"Olanzapine and warfarin drug interaction.","volume":"61","author":"Maya JF","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_6_118_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199007000-00005"},{"key":"e_1_2_6_119_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-198903000-00010"},{"key":"e_1_2_6_120_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.28.1.41"},{"key":"e_1_2_6_121_2","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(89)90064-8"},{"key":"e_1_2_6_122_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1985.tb04052.x"},{"key":"e_1_2_6_123_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199608000-00007"},{"key":"e_1_2_6_124_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1991.tb05587.x"},{"key":"e_1_2_6_125_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199304000-00004"},{"key":"e_1_2_6_126_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1988.198"},{"key":"e_1_2_6_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(90)90022-T"},{"key":"e_1_2_6_128_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.1996.361"},{"key":"e_1_2_6_129_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199702000-00007"},{"key":"e_1_2_6_130_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199610000-00007"},{"key":"e_1_2_6_131_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199704000-00003"},{"key":"e_1_2_6_132_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199502000-00004"},{"key":"e_1_2_6_133_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199710000-00011"},{"key":"e_1_2_6_134_2","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.1996.0414"},{"key":"e_1_2_6_135_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199710000-00004"},{"key":"e_1_2_6_136_2","first-page":"234","article-title":"Correlation of human cytochrome P4502C substrate specificities with primary structure: Warfarin as a probe.","volume":"43","author":"Kaminsky LS","year":"1993","journal-title":"Mol Pharmacol"},{"key":"e_1_2_6_137_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199402000-00005"},{"key":"e_1_2_6_138_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199706000-00005"},{"key":"e_1_2_6_139_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199512000-00008"},{"key":"e_1_2_6_140_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199710000-00010"},{"key":"e_1_2_6_141_2","first-page":"375","article-title":"Polymerase chain reaction directed identification, cloning and quantitation of CYP2C18 mRNA.","volume":"40","author":"Furuya H","year":"1991","journal-title":"Mol Pharmacol"},{"key":"e_1_2_6_142_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1993.1803"},{"key":"e_1_2_6_143_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00025a008"},{"key":"e_1_2_6_144_2","first-page":"515","article-title":"Characterisation of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal livers and adult lungs.","volume":"24","author":"Shimada T","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_145_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(95)02184-1"},{"key":"e_1_2_6_146_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(94)90223-2"},{"key":"e_1_2_6_147_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840130622"},{"key":"e_1_2_6_148_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198900171-00007"},{"key":"e_1_2_6_149_2","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(88)90115-5"},{"key":"e_1_2_6_150_2","first-page":"175","article-title":"Effect of age on disposition of warfarin enantiomers.","volume":"61","author":"Horn JR","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_6_151_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199550020-00003"},{"key":"e_1_2_6_152_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280055"},{"key":"e_1_2_6_153_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198308040-00006"},{"key":"e_1_2_6_154_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.45.8.704"},{"key":"e_1_2_6_155_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199304000-00003"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.1998.00721.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.1998.00721.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1365-2125.1998.00721.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.1998.00721.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T20:42:55Z","timestamp":1704314575000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2125.1998.00721.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,6]]},"references-count":154,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1998,6]]}},"alternative-id":["10.1046\/j.1365-2125.1998.00721.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2125.1998.00721.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,6]]}}}